CareDx (CDNA) and TC Biopharm (TCBP) said Wednesday they have struck a partnership under which CareDx will carry out pharmacokinetic analysis through its AlloCell test in the Achieve clinical study of allogeneic gamma delta T cell therapy TCB008.
Financial terms weren't disclosed.
The trial will evaluate the effectiveness and efficacy of TCB008 for participants with acute myeloid leukemia or myelodysplastic syndrome, the companies added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments